-
In this interactive presentation, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, reviews current guidelines and emerging data on selecting oral antiplatelet therapies, including the optimal duration of dual antiplatelet therapy in selected patients.
-
Results from a recent subanalysis of the DAPT study have the potential to help clinicians address the challenging question of whether to extend DAPT duration for patients with coronary stents.
-
In this downloadable slideset, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, reviews current guidelines and emerging data on selecting oral antiplatelet therapies, including the optimal duration of dual antiplatelet therapy in selected patients.
|
Latest Content
-
| Akshay Suvas Desai MD, MPH - 10/10/2016 |
1 comment / Last Comment: 10/11/2016 |
I describe how biomarkers such as BNP and NT-proBNP can help influence decisions about the diagnosis and prognosis of heart failure.
-
In this CME-certified video module, Keith C. Ferdinand, MD, FACC, FAHA, discusses approaches to recognizing patients with elevated HF risk, using biomarkers to support HF diagnosis and prognosis, and integrating the latest treatment options into evidence-based management therapies, with a focus on treating special patient populations.
Faculty: Keith C. Ferdinand MD, FACC, FAHA
Released: 8/31/2016
-
In this downloadable slideset, Keith C. Ferdinand, MD, FACC, FAHA, reviews risk factors for HF, the use of biomarkers to support HF diagnosis and prognosis, and the latest HF treatment strategies, with a focus on treating special patient populations.
Date Posted: 8/31/2016
-
| Christopher P. Cannon MD - 1/22/2016 |
3 comments / Last Comment: 8/26/2016 |
Results from a recent subanalysis of the DAPT study have the potential to help clinicians address the challenging question of whether to extend DAPT duration for patients with coronary stents.
-
| Joshua A. Beckman MD - 12/9/2015 |
6 comments / Last Comment: 8/26/2016 |
In my approach to antiplatelet therapy for patients with PAD, I maximize available data and draw from coronary guidelines when necessary.
-
| Javed Butler MD, MPH, MBA - 10/8/2015 |
8 comments / Last Comment: 2/14/2017 |
A paucity of randomized data has led to a wide range of clinical practices regarding the delivery and dosing of loop diuretics in patients with acute heart failure. Here’s my approach.
-
In this interactive presentation, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, reviews current guidelines and emerging data on selecting oral antiplatelet therapies, including the optimal duration of dual antiplatelet therapy in selected patients.
Faculty: Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC
Released: 10/2/2015
-
In this downloadable slideset, Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, reviews current guidelines and emerging data on selecting oral antiplatelet therapies, including the optimal duration of dual antiplatelet therapy in selected patients.
Date Posted: 10/2/2015
-
In this downloadable slideset, G. Michael Felker, MD, MHS, FACC, FAHA, and Javed Butler, MD, MPH, MBA, discuss recent data concerning the diagnosis and management of acute heart failure, including the use of biomarkers in diagnosis and prognosis, benefits and limitations of current standards of care, and evidence regarding investigational therapeutics.
Date Posted: 7/24/2015
-
In this CME-certified interactive online program, G. Michael Felker, MD, MHS, FACC, FAHA, and Javed Butler, MD, MPH, MBA, discuss recent data concerning the diagnosis and management of acute heart failure, including the use of biomarkers in diagnosis and prognosis, benefits and limitations of current standards of care, and evidence regarding investigational therapeutics.
Faculty: G. Michael Felker MD, MHS, FACC, FAHA, Javed Butler MD, MPH, MBA
Released: 7/24/2015
|
|
|